12.12.25 -- Building Patient-Driven Culture And Leadership Resilience In CGT

To successfully bring innovative gene therapies to patients with neurological disorders, drug sponsors must design safe and compliant clinical trials with rigorous approaches to ethics and consent.

Clinical trials should reflect the affected population by reducing participation barriers and bringing trials to patients to increase inclusion and improve real-world data.

Many clinical trial oversight problems can be avoided or mitigated by sponsor understanding root causes and being a proactive collaborator with its partners.

How can you turn capacity limits into enrollment momentum and ensure timelines stay on track while also expanding access to diverse patient populations?

Explore how collaboration between researchers and Patient Advocacy Groups (PAGs) can bridge the trust gap that undermines recruitment and can make trial participation more approachable and meaningful.

Vendor selection often fails due to five common dysfunctions. Identifying and addressing them early improves alignment, trust, and trial performance—avoiding costly delays.

Top-performing clinical trials treat recruitment as a science — thinking like patients, acting fast, and engaging communities with intention, not outdated tactics like bulletin board flyers.

Here, the author introduces a new framework for GA clinical development that integrates genetic profiling, novel biomarkers, and predictive analytics to improve precision, streamline design, and accelerate development.

Recruitment hurdles are overcome by leveraging engaged, data-sharing patient communities. See how a strategic, patient-centric approach delivered a pre-qualified clinical trial cohort quickly and efficiently.

Dive into how refrigerators, freezers, and incubators are vital to scientific progress to preserve samples, support experiments, and ensure the integrity of life-saving research in every modern laboratory.

Uncover why single-use cold-chain containers made with polytetrafluoroethylene fluoropolymers may be less susceptible to failure and breakage at cold temperatures.